VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. West Explains the Pemetrexed Clinical Trial

H. Jack West, MD
Published: Friday, Jul 22, 2011



H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington, describes progression free survival (PFS) for patients with advanced nonsquamous non–small cell lung cancer (NSCLC) in the PARAMOUNT phase III trial examining continuation maintenance therapy in two randomized arms; one receiving pemetrexed in addition to best supportive care and the other placebo and best supportive care.


H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington, describes progression free survival (PFS) for patients with advanced nonsquamous non–small cell lung cancer (NSCLC) in the PARAMOUNT phase III trial examining continuation maintenance therapy in two randomized arms; one receiving pemetrexed in addition to best supportive care and the other placebo and best supportive care.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x